XF-73 data abstract to be presented at 2021 ECCMID

  • XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours
  • Excellent clinical safety profile for XF-73 dosed in patients scheduled for cardiac surgery
  • Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom – 10th June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of  XF-73 nasal gel has been accepted for presentation at Europe’s premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), to be held 9 – 12 July, 2021.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH